Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDMETH: Methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis
2024-514055-15-00Phase 4Authorised
- Sponsor
- Erasmus MC
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in pulmonary sarcoidosis comparing Methotrexate arm with Prednisone arm (2 arms). Primary endpoint: Change in hospital-measured Forced Vital Capacity. Planned start Nov 2024; status: authorised.
02
Drugs
methotrexateprednisone
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on 2024-514055-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514055-15-00.